GeoVax Labs (NASDAQ:GOVX) Downgraded by D. Boral Capital to “Hold”

GeoVax Labs (NASDAQ:GOVX) was downgraded by equities research analysts at D. Boral Capital from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Several other brokerages have also recently weighed in on GOVX. Wall Street Zen cut shares of GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, GeoVax Labs currently has a consensus rating of “Hold” and an average target price of $187.50.

GeoVax Labs Price Performance

Shares of GeoVax Labs stock opened at $1.39 on Thursday. The firm’s 50-day moving average is $3.89 and its 200 day moving average is $11.00. GeoVax Labs has a 1 year low of $1.26 and a 1 year high of $47.13. The stock has a market cap of $2.40 million, a price-to-earnings ratio of -0.04 and a beta of 3.77.

Hedge Funds Weigh In On GeoVax Labs

A number of large investors have recently made changes to their positions in the business. Sabby Management LLC acquired a new stake in shares of GeoVax Labs during the third quarter worth about $313,000. Renaissance Technologies LLC purchased a new position in GeoVax Labs during the 4th quarter worth approximately $104,000. Jane Street Group LLC acquired a new stake in GeoVax Labs during the 4th quarter valued at approximately $99,000. Armistice Capital LLC acquired a new stake in GeoVax Labs during the 3rd quarter valued at approximately $253,000. Finally, HRT Financial LP purchased a new stake in shares of GeoVax Labs in the 4th quarter valued at $31,000. 6.09% of the stock is owned by institutional investors and hedge funds.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.